It can provide new strategies and methods for treating myocardial infarction, and with further research and clinical validation of cGAS-STING inhibitors, they have the potential to become a new option for the treatment of ischemia–reperfusion injury following myocardial infarction, improving patient prognosis and quality of life. The gene discussed is CGAS; the disease is myocardial infarction.